Vitamin D, NSAIDS provide double whammy against prostate cancer
..."The group saw a 25 percent reduction in prostate cell growth using only
calcitriol, and approximately the same reduction using only ibuprofen and
naproxen. But when they combined calcitriol and an NSAID, they saw up to a 70
percent reduction. This result was obtained using from one-half to one-tenth the
concentration required for either of the drugs used alone."...
The favoured cash cow but generally toxic drugs are shamelessly and continually
touted as the only disease management tool at our disposal!
Here is yet again another example of how generally non toxic and cost effective
vitamins can be used by those in the know and are clearly the future for
disease prevention and/or cure.
The importance of the sun exposure and nutrients such as
cod live oil, pooh poohed by the mainstream, is a must if we are to stay
healthy. Suspect a better alternative to
NSAIDS may well be
Turmeric. Don't hold your breath, as usual, no one is going check this out
for you no matter how compelling the case!
See also:
Many Costs of Lowering PSA Cutoff: Study
Chris Gupta
http://tinyurl.com/dabxo
-------------------
Vitamin D, NSAIDS provide double whammy
against prostate cancer, Stanford study finds
STANFORD, Calif. - The growth of prostate cancer cells can be halted by
combining a form of vitamin D, available only by prescription, with low doses of
an over-the-counter painkiller, researchers at the Stanford University School of
Medicine have found. The combination reduced prostate cancer cell growth in a
laboratory dish by up to 70 percent, according to the findings, published in the
Sept. 1 issue of Cancer Research.
The study's senior author, David Feldman, MD, professor of medicine, who has
been studying vitamin D for 25 years, had shown in previous studies that a form
of the vitamin, known as calcitriol, limits the growth of prostate cancer
cells. Calcitriol, the active form of vitamin D, is the metabolite that is
created in the body after consumption of vitamin D-containing food or exposure
to the sun.
Feldman wanted to see if he could boost calcitriol's effects and lower the
dose by using it in conjunction with another drug. He and his colleagues,
including professor of urology Donna Peehl, PhD, who specializes in developing
models of prostate cancer in cultured cells, found that by using calcitriol with
nonsteroidal anti-inflammatory drugs, or NSAIDs, they could suppresses prostate
cancer growth in vitro even more-and with smaller doses-than using either drug
alone.
"There is great enhancement when the drugs are given together, using what we
think is a safe dose in humans," said Feldman. "It's hard to make an exact
comparison, as we are talking about cells in a dish and not a person." Still,
based on the findings, he and his colleagues have already begun a clinical trial
in men who have a post-treatment recurrence of prostate cancer. Both calcitriol
and nonselective NSAIDs have been used in humans for years, and the safety and
risks of these drugs are well known.
According to the Centers for Disease Control and Prevention, nearly 30,000 men
die annually in the United States from prostate cancer. Among cancers, only lung
cancer kills more men. Although prostate cancer is often a slow-growing,
noninvasive type of cancer, there are some cases where a deadly migration of
cancer cells invades other parts of the body. The standard treatment for such
cases is hormone therapy, but that treatment ultimately does not work for most
patients. Slowing the growth of the prostate cancer cells could buy time for
patients before beginning this last-ditch therapy.
Over the course of Feldman's years of vitamin D research, he and others had
determined that the vitamin has several actions that make it useful in cancer
therapy. While a great deal is now known about these effects, there is still
much to be learned about how the vitamin stymies tumor growth.
To get an idea of what calcitriol does on a genetic level to halt tumor growth,
the researchers used a cDNA microarray, a tool that provides an overview of the
genetic changes that occur when prostate cancer cells react to calcitriol. The
researchers discovered that two of the affected genes are critical in the
production and breakdown of prostaglandins - hormones that cause a range of
physiological effects, including inflammation. Inflammation, in turn, is also
associated with cancer growth.
Like calcitriol, NSAIDs also block prostaglandin production. Thus, it seemed
logical to test calcitriol in various combinations with NSAIDs to see if the
double whammy could knock out prostate cancer better than either drug alone,
explained study leader Jacqueline Moreno, PhD, a postdoctoral scholar in
Feldman's lab.
When the researchers began the study, which was done on cells in culture, they
were using selective NSAIDs, such as Vioxx and Celebrex. These drugs
specifically target the prostaglandin pathway, reducing the gastrointestinal
side effects of the nonselective NSAIDs. But after Vioxx was pulled from the
market last year due to cardiovascular risks, the researchers switched to using
two nonselective NSAIDs, ibuprofen and naproxen, so that the controversy over
selective NSAIDs wouldn't cast a shadow over their work.
The group saw a 25 percent reduction in prostate cell growth using only
calcitriol, and approximately the same reduction using only ibuprofen and
naproxen. But when they combined calcitriol and an NSAID, they saw up to a 70
percent reduction. This result was obtained using from one-half to one-tenth the
concentration required for either of the drugs used alone.
The group's findings are the basis of a new clinical trial Feldman has begun
with oncologist Sandy Srinivas, MD, assistant professor of medicine. Men who
have been treated for prostate cancer, but who are experiencing a recurrence,
take naproxen twice a day combined with a high, once-weekly dose of calcitriol.
Weekly administration of calcitriol avoids a pitfall of earlier studies that
used daily dosing: too much calcium in the blood, a condition called
hypercalcemia, which can lead to kidney stones.
Feldman's group uses calcitriol for both the cell culture studies and the
clinical trial to ensure that enough of the active form of vitamin D is in the
patients to be effective. Feldman emphasized that calcitriol is available by
prescription only. "We don't want the patient to think that if they take
over-the-counter vitamin D, it will work in the same way," he said.
###
Staff research scientist Aruna Krishnan, PhD, research associate Srilatha Swami,
PhD, and urology postdoctoral scholar Larisa Nonn, PhD, also contributed to this
work, which was funded by grants from the National Institutes of Health and the
Department of Defense.
Stanford University Medical Center integrates research, medical education and
patient care at its three institutions - Stanford University School of Medicine,
Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford.
For more information, please visit the Web site of the medical center's Office
of Communication & Public Affairs at
mednews.stanford.edu.
PRINT MEDIA CONTACT: Mitzi Baker at (650) 725-2106 (mabaker@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)